Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical ...

Cumberland Pharmaceuticals Inc. (CPIX) is a rarely covered biotech company headquartered in Nashville, Tennessee. It completed its initial public offering (“IPO”) in 2009, raising ~$85m at $17 per ...

Creative Biolabs provides customized support across key stages of lipid-based therapeutic development, helping researchers optimize delivery systems for different types of therapeutic payloads, ...

Biosimulation Market Biosimulation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Biosimulation Market by Phase, Modality, Application, Indication, End User - Global Forecast to 2031" has been ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Fortrea (NASDAQ:FTRE) and the best and ...

Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip ...

Artificial intelligence (AI)-based clinical monitoring agents can deliver gains of up to $21m per drug development programme, as well as an 82-times return on investment (ROI), a study has found.

Generative biology is moving from code to the clinic, promising faster drug discovery while raising hard questions about ...

Across the pharmaceutical industry, innovation has always been driven by a fundamental commitment to developing therapies that meaningfully improve patients’ lives. It’s a commitment that carries ...

In this New Scientist CoLab podcast, experts from global life sciences leader Cytiva explain the hidden, high-stakes science ...

Evan Feinberg founded Genesis Molecular AI seven years ago to take his research at Stanford on AI for drug discovery to the real world. Today the company announced its biggest partnership to date: A ...

By Laurie Chen SHANGHAI, July 23 (Reuters) - Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said, ...